Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 226Breast Neoplasms 223Prostatic Neoplasms 163Multiple Myeloma 147Neoplasms 130Leukemia, Myeloid, Acute 117Colorectal Neoplasms 117Lung Neoplasms 112Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 90Carcinoma, Hepatocellular 88Melanoma 83Lymphoma 81Triple Negative Breast Neoplasms 74Pancreatic Neoplasms 73Ovarian Neoplasms 72Sarcoma 66Lymphoma, Large B-Cell, Diffuse 63Carcinoma, Renal Cell 63Brain Neoplasms 62Recurrence 58Head and Neck Neoplasms 57Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Leukemia, Lymphocytic, Chronic, B-Cell 53Urinary Bladder Neoplasms 52Hematologic Neoplasms 52Lymphoma, Non-Hodgkin 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47

Interventions

darolutamide 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × High-Risk Localized Prostate Cancer × 90 days × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡